Automated differential cell counters
This article was originally published in The Gray Sheet
Executive Summary
Downclassification of the devices used with immature or abnormal blood cells from Class III to Class II with special controls based on information submitted in a reclassification petition by the International Society for Laboratory Hematology is effective Feb. 13, FDA announces in the Jan. 14 Federal Register. FDA's Dec. 4, 2001 1automated differential cell counter final guidance will serve as a special control...
You may also be interested in...
CDRH-Wide Preamendments Reclassifications Could Finish In 2-3 Years
CDRH's Division of Clinical Laboratory Devices anticipates wrapping up preamendments reclassifications in six to 12 months
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.